Stocks · News reference
Chemours PFAS settlement lifts shares as the $455 million deal clarifies liabilities, payment timing and future escrow obligations.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Chemours (NYSE:CC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.
On October 1, 2026, Corteva Inc. (NYSE:CTVA) completed the spin-off of its seed operating segment into Vylor Inc. (NYSE:VYLR) through a pro rata distribution to holders of record as of the close of business on September
Analysts upgraded NetApp, Humana, Corteva, Afya, with price-target changes for four stocks.
Keybanc analyst Salvator Tiano upgrades Corteva (NYSE:CTVA) from Sector Weight to Overweight and announces $17 price target.